Balance is a double blind, placebo controlled phase 3 study of Akcea-APOCIII-LRX administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant (CLEAR).

COORDINATE-Diabetes is a cluster-randomized clinical trial testing the effectiveness of an innovative, clinic level intervention to improve the management of type 2 Diabetes in patients with cardiovascular disease.

The purpose of this extension study is to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study will be a global multicenter study.

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.